Exhibit 99.1
Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results
and Provides Business Update
Company on Track to File NDA in 3Q 2016 for RhopressaTM
(netarsudil ophthalmic solution) 0.02%
Mercury 1 Phase 3 Topline Readout for RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Also Expected in 3Q 2016
Conference Call and Webcast Today, May 2, at 5:00 p.m. ET
IRVINE, California – (BUSINESS WIRE) – Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2016, along with a general business update.
Aerie Highlights
| • | Aerie remains well positioned to file its NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02% in the third quarter of 2016. |
| • | The first Phase 3 clinical trial for RoclatanTM(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, Mercury 1, is nearly completely enrolled, and its 90-day topline interim efficacy readout remains on track for the third quarter of 2016. Mercury 2, the second Phase 3 clinical trial for RoclatanTMwhich commenced in March of 2016, is enrolling on schedule. |
| • | Rocket 4, the Phase 3 clinical trial for RhopressaTM designed to provide adequate safety data for approval by European regulatory authorities, also remains on schedule for topline 90-day efficacy readout in the fourth quarter of 2016. |
| • | New preclinical research being presented at the Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology) provides further valuable insights into RhopressaTM, including its potential to reverse fibrosis in trabecular meshwork cells as well as importantin vivo research on the potential of RhopressaTMto increase trabecular meshwork outflow. |
| • | As of March 31, 2016, Aerie had $130.8 million in cash, cash equivalents, and investments on the balance sheet. For the first quarter of 2016, net cash burn totaled $19.7 million, on track with the full-year guidance provided earlier this year. |
“We are rapidly approaching two very important milestones with our upcoming NDA filing for RhopressaTM and the readout of Mercury 1 topline Phase 3 data for RoclatanTM, both expected in the third quarter of this year. Ophthalmologist responses to the efficacy and safety profiles of our product candidates have been very positive and appear to be fully aligned with our expected market positioning of both product candidates. We also continue to observe promising evidence of the disease modification and neuroprotective potential of RhopressaTMin preclinical studies, and we have commenced research to evaluate sustained release formulation technologies that could have the capability of delivering RhopressaTM over several months to the front of the eye for glaucoma” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer.
Dr. Anido continued, “Looking beyond the U.S. markets, we are evaluating our strategies for success in Europe and Japan, which represent very large glaucoma markets, and expect to have a clear view of our path forward in these geographies by the end of 2016.”
First Quarter 2016 Financial Results
As of March 31, 2016, Aerie had cash, cash equivalents, and investments of $130.8 million on the balance sheet. For the first quarter ended March 31, 2016, Aerie reported a net loss attributable to common stockholders, as measured in accordance with U.S. generally accepted accounting principles (“GAAP”), of $22.7 million, or $0.85 per share, compared to $17.2 million and $0.70 per share for the first quarter of 2015. The weighted average number of shares of common stock outstanding utilized in the calculation of net loss per common share was 26,723,266 and 24,602,668 for the first quarters of 2016 and 2015, respectively.
The $22.7 million net loss attributable to common stockholders for the first quarter of 2016 includes $22.1 million in operating expenses, reflecting $12.3 million in research and development expenses and $9.8 million in general and administrative expenses. Excluding $3.5 million of non-cash stock-based compensation expense, adjusted operating expenses for the first quarter of 2016 were $18.6 million, with adjusted research and development expenses of $11.6 million and adjusted general and administrative expenses of $7.0 million. Total adjusted net loss for the first quarter of 2016 was $19.2 million and adjusted net loss per share was $0.72.
The $17.2 million net loss attributable to common stockholders for the first quarter of 2015 reflects research and development expenses of $11.6 million and general and administrative expenses of $8.0 million. Excluding $2.7 million of non-cash stock-based compensation expense, adjusted operating expenses for the first quarter of 2015 were approximately $16.9 million, reflecting adjusted research and development expenses of $11.1 million and adjusted general and administrative expenses of $5.8 million. Total adjusted net loss for the first quarter of 2015 was $14.5 million and adjusted net loss per share was $0.59.
The higher operating expenses in the first quarter of 2016 as compared to the first quarter 2015 primarily reflect increased activities associated with the expansion of our employee base to support the growth of our operations, including clinical activities related to our Phase 3 programs for our product candidates, and preparatory activities associated with our commercialization efforts.
Conference Call / Web Cast Information
Aerie management will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss Aerie’s financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. Please connect to Aerie’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 91168311. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 91168311. The telephone replay will be available until May 9, 2016.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie’s two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. It is expected that the NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place in the second half of 2017. In addition, Aerie is further building its pipeline, including through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval
of, or other action with respect to, our product candidates; our expectations regarding the commercialization of our product candidates; our expectations related to the use of proceeds from our initial public offering and the issuance and sale of our senior secured convertible notes and the issuance and sale of shares of our common stock in connection with our “at the market” sales agreements; our estimates regarding anticipated capital requirements and our needs for additional financing; the potential advantages of our product candidates; our plans to pursue development of our product candidates for additional indications and other therapeutic opportunities; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma; and our ability to protect our proprietary technology and enforce our intellectual property rights; and our expectations regarding strategic operations, including our ability to in-license or acquire additional ophthalmic products or product candidates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). In particular, the preclinical research discussed in this press release is preliminary and the outcome of such preclinical studies may not be predictive of the outcome of later clinical trials. Any future clinical trial results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the preclinical research findings discussed in this press release. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Non-GAAP Financial Measures
To supplement our financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures, some of which are discussed above: adjusted net loss, adjusted operating expenses, adjusted research and development expenses, adjusted general and administrative expenses, adjusted other income (expense) and adjusted net loss per share. For a description of the adjusted calculations and reconciliations to the nearest GAAP measures, please see the “Reconciliation of GAAP Net Loss to Adjusted Net Loss” and “Reconciliation of GAAP Net Loss per Share to Adjusted Net Loss per Share” tables in this press release.
We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.
The presentation of these financial measures is not intended to be considered in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, the
adjustments to our GAAP financial measures reflect the exclusion of non-cash stock-based compensation expense, which is recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures.
AERIE PHARMACEUTICALS, INC.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share data)
| MARCH 31, 2016 | DECEMBER 31, 2015 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 74,266 | $ | 91,060 | ||||
Short-term investments | 45,023 | 45,502 | ||||||
Prepaid expenses and other current assets | 1,402 | 1,865 | ||||||
|
|
|
| |||||
Total current assets | 120,691 | 138,427 | ||||||
Long-term investments | 11,480 | 13,808 | ||||||
Furniture, fixtures and equipment, net | 3,993 | 3,816 | ||||||
Other assets, net | 3,037 | 3,076 | ||||||
|
|
|
| |||||
Total assets | $ | 139,201 | $ | 159,127 | ||||
|
|
|
| |||||
Liabilities and Stockholders’ (Deficit) Equity | ||||||||
Current liabilities | ||||||||
Accounts payable and other current liabilities | $ | 15,501 | $ | 16,565 | ||||
Interest payable | 545 | 551 | ||||||
|
|
|
| |||||
Total current liabilities | 16,046 | 17,116 | ||||||
Convertible notes, net of discounts | 123,310 | 123,236 | ||||||
|
|
|
| |||||
Total liabilities | 139,356 | 140,352 | ||||||
|
|
|
| |||||
Commitments and contingencies | ||||||||
Stockholders’ (deficit) equity | ||||||||
Preferred stock, $0.001 par value; 15,000,000 shares authorized as of March 31, 2016 and December 31, 2015; None issued and outstanding | — | — | ||||||
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2016 and December 31, 2015; 26,518,449 and 26,458,495 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively | 27 | 26 | ||||||
Additional paid-in capital | 240,154 | 236,492 | ||||||
Accumulated other comprehensive loss | (68 | ) | (179 | ) | ||||
Accumulated deficit | (240,268 | ) | (217,564 | ) | ||||
|
|
|
| |||||
Total stockholders’ (deficit) equity | (155 | ) | 18,775 | |||||
|
|
|
| |||||
Total liabilities and stockholders’ (deficit) equity | $ | 139,201 | $ | 159,127 | ||||
|
|
|
| |||||
AERIE PHARMACEUTICALS, INC.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share data)
| THREE MONTHS ENDED MARCH 31, | ||||||||
| 2016 | 2015 | |||||||
Operating expenses | ||||||||
General and administrative | $ | (9,801 | ) | $ | (8,023 | ) | ||
Research and development | (12,309 | ) | (11,618 | ) | ||||
|
|
|
| |||||
Loss from operations | (22,110 | ) | (19,641 | ) | ||||
Other income (expense), net | (548 | ) | 2,402 | |||||
|
|
|
| |||||
Net loss before income taxes | (22,658 | ) | (17,239 | ) | ||||
Income tax expense | (46 | ) | — | |||||
|
|
|
| |||||
Net loss | $ | (22,704 | ) | $ | (17,239 | ) | ||
|
|
|
| |||||
Net loss attributable to common stockholders – basic and diluted | $ | (22,704 | ) | $ | (17,239 | ) | ||
|
|
|
| |||||
Net loss per share attributable to common stockholders – basic and diluted | $ | (0.85 | ) | $ | (0.70 | ) | ||
|
|
|
| |||||
Weighted average number of common shares outstanding – basic and diluted | 26,723,266 | 24,602,668 | ||||||
|
|
|
| |||||
Net loss | (22,704 | ) | (17,239 | ) | ||||
Unrealized gain on available-for-sale investments | 111 | 49 | ||||||
|
|
|
| |||||
Comprehensive loss | $ | (22,593 | ) | $ | (17,190 | ) | ||
|
|
|
| |||||
Aerie Pharmaceuticals, Inc.
Reconciliation of GAAP Net Loss to Adjusted Net Loss
(Unaudited)
(in thousands)
| THREE MONTHS ENDED MARCH 31, | ||||||||
| 2016 | 2015 | |||||||
Net loss attributable to common stockholders – basic and diluted: | ||||||||
Net loss attributable to common stockholders – basic and diluted (GAAP) | $ | (22,704 | ) | $ | (17,239 | ) | ||
Adjustments: | ||||||||
Stock-based compensation (a) | 3,534 | 2,741 | ||||||
|
|
|
| |||||
Adjusted Net loss | $ | (19,170 | ) | $ | (14,498 | ) | ||
|
|
|
| |||||
Operating expenses: | ||||||||
General and administrative expense: | ||||||||
General and administrative expense (GAAP) | $ | (9,801 | ) | $ | (8,023 | ) | ||
Adjustments: | ||||||||
Stock-based compensation (a) | 2,822 | 2,230 | ||||||
|
|
|
| |||||
Adjusted general and administrative expense | $ | (6,979 | ) | $ | (5,793 | ) | ||
|
|
|
| |||||
Research and development expense: | ||||||||
Research and development expense (GAAP) | $ | (12,309 | ) | $ | (11,618 | ) | ||
Adjustments: | ||||||||
Stock-based compensation (a) | 712 | 511 | ||||||
|
|
|
| |||||
Adjusted research and development expense | $ | (11,597 | ) | $ | (11,107 | ) | ||
|
|
|
| |||||
Operating expenses (GAAP) | $ | (22,110 | ) | $ | (19,641 | ) | ||
Adjustments: | ||||||||
Stock-based compensation (a) | 3,534 | 2,741 | ||||||
|
|
|
| |||||
Adjusted operating expenses | $ | (18,576 | ) | $ | (16,900 | ) | ||
|
|
|
| |||||
Other income (expense): | ||||||||
Other income (expense) (GAAP) | $ | (548 | ) | $ | 2,402 | |||
Adjustments: | ||||||||
| — | — | |||||||
|
|
|
| |||||
Adjusted other income (expense) | $ | (548 | ) | $ | 2,402 | |||
|
|
|
| |||||
Aerie Pharmaceuticals, Inc.
Reconciliation of GAAP Net Loss Per Share to Adjusted Net Loss Per Share
(Unaudited)
| THREE MONTHS ENDED MARCH 31, | ||||||||
| 2016 | 2015 | |||||||
Net loss per share attributable to common stockholders – basic and diluted: | ||||||||
Net loss per share attributable to common stockholders – basic and diluted (GAAP) | $ | (0.85 | ) | $ | (0.70 | ) | ||
Adjustments: | ||||||||
Stock-based compensation (a) | 0.13 | 0.11 | ||||||
|
|
|
| |||||
Adjusted Net loss per share | $ | (0.72 | ) | $ | (0.59 | ) | ||
|
|
|
| |||||
Weighted average number of common shares outstanding – basic and diluted | 26,723,266 | 24,602,668 | ||||||
|
|
|
| |||||
Aerie is providing adjusted information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.
Explanation of adjustments:
(a) Stock-based compensation: Exclude the non-cash stock-based compensation.
Contacts
Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com